

# Nasal high flow (NHF) in pediatric care

starting at flow rates of 2 L/kg/min can:

ED boarders<sup>1-3</sup>
intubations<sup>1-4</sup>
patient escalation<sup>3</sup>
cost savings<sup>2,5</sup>
length of stay<sup>6</sup>

Wing et al. Pediatric Emergency Care 28, 1117-1123 (2012).
Mayfield et al. J Pediatric Child Health 50, 373-378 (2014).
Franklin et al. N Engl J Med 378, 1121-1131 (2018).
Schibler et al. Intensive Care Med 37, 847-852 (2011).
Willer et al. Hosp Pediatr 11, 891-895 (2021).
Ramnarayan et al. JAMA 328(2), 162-172 (2022).





# Mechanisms of action

Respiratory support

Washout of anatomical dead space<sup>4</sup>

Airway hydration

Accurate oxygen delivery<sup>7,8</sup>

## NHF definition:<sup>1-3</sup>

Nasal high flow (NHF) is a mode of noninvasive respiratory support that delivers high flows of heated and humidified blended air and oxygen through an unsealed nasal interface.

1. Wilkinson D et al. Cochrane Database Sys Rev (2016); 2. Collins CL et al. J Pediatr 162(5):949-954 (2013); 3. Franklin D et al. N Engl J Med 1121-1131 (2018).



Patient comfort<sup>9,10</sup>



# **NHF** benefits

NHF offers a range of benefits compared with standard oxygen therapy, and there are several mechanisms of action associated with this therapy, including airway hydration and reduction of anatomical dead space.

A systematic search of available literature shows there are more than 220 peer-reviewed papers investigating the use of NHF therapy in infants and children.

Of these, 31 are randomized controlled trials (RCTs) - they compared NHF with standard oxygen therapy, continuous positive airway pressure (CPAP) and alternative treatments.

2013

France

Milési et al.<sup>4</sup>

2011

Australia

Schibler et al.<sup>2</sup>

2014

Testa et al.6





2014

Pham et al.<sup>8</sup>

Australia, New Zealand

RCT showing NHF had a longer compared with standard oxygen therapy for children with acute hypoxemic respiratory failure.

## **Reduce ED boarders**

## **Reduce intubations**

Schibler et al. 2011. Intensive Care Medicine<sup>1</sup>

Mayfield et al. 2014. Journal of Paediatrics and Child Health<sup>2</sup>











- Nonresponders requiring PICU admission can be identified within the first hour of NHF treatment by monitoring HR and RR.<sup>1,2</sup>
- Infants receiving NHF at 2 L/kg/min were 4 times less likely to be admitted to PICU than those receiving standard  $O_2$ <sup>2</sup>

Note: Standard  $O_2 = 100\% O_2$ ; NHF at 2 L/kg/min = Total flow/kg/min; FiO<sub>2</sub> titrated

#### Responders to NHF (Mayfield 2014)

13% of patients did not respond to NHF and were admitted to PICU.

87% of patients responded to NHF and remained on the floor when using 2 L/kg/min vs. standard O<sub>2</sub>.<sup>2</sup>



Wing et al. 2012. Pediatric Emergency Care<sup>1</sup>

12		
10		
8	11%	
6		
4		
2		
0		2%
	No NHF use in ED	NHF use with guid

• Implementation of an NHF guideline was associated with a reduced intubation rate in the ED.



• Increasing use of NHF led to reduced intubation rates in the PICU.

# **Reduce patient escalation**

# Cost effectiveness of standardized NHF in the ED/floor

#### Franklin et al. 2018. The New England Journal of Medicine<sup>1</sup>



(< 12 months) with bronchiolitis



#### Primary outcome

- Patients receiving NHF at 2 L/kg/min are half as likely to fail vs. standard  $O_2 < 2$  L/min.
- All patients who failed standard O<sub>2</sub> received rescue NHF. - 61% of them responded to NHF and avoided PICU.

Note: Standard O<sub>2</sub> = 100% O<sub>2</sub>. NHF at 2 L/kg/min = Total flow/kg/min; FiO<sub>2</sub> titrated

### Therapy failure



1 in 9 patients met therapy failure on NHF

1 in 4 patients met therapy failure on standard O<sub>2</sub>



Those who received NHF had significantly lower rates of escalation of care due to therapy failure than those receiving standard  $O_2$  (p < 0.001).<sup>1</sup>



### Introducing NHF in the ED

Mayfield et al. 2014<sup>1</sup> Journal of Paediatrics and Child Health 30 31% 25 20

> Standard O<sub>2</sub> NHF < 2 L/min 2 L/kg/min

13%

15

10

5

0

#### Age-based vs. weight-based NHF

Willer et al. 2021<sup>2</sup> Hospital Pediatrics



#### New NHF users in the ED

- PICU admissions reduced by 18%.
- Estimated US\$850K savings per year by avoiding PICU (for a 19-bed PICU).

 PICU admissions reduced by 6.2%. US\$661 savings per bronchiolitis patient by avoiding PICU.

Standard  $O_2 = 100\% O_2$ NHF at 2 L/kg/min = Total flow/kg/min; FiO<sub>2</sub> titrated.

#### 1. Mayfield et al. J Pediatric Child Health 50, 373–378 (2014); 2. Willer et al. Hosp Pediatr 11, 891–895 (2021); 3. Vijay et al. Arch Dis Child 105, 975–980 (2020); 4. Franklin et al. N Engl J Med 378, 1121–1131 (2018).



#### NHF users, refining protocols

#### Experienced NHF user, hospital wide

- No statistically significant difference in PICU admissions due to use of rescue NHF.
- Cost neutral.

Note: Cost analysis of the PARIS 1 study.4

# Reduce length of stay and sedation

# What affects patient throughput?



\* Adjusted for prebaseline characteristics 1. Ramnarayan et al. JAMA 328(2), 162–172 (2022). Patients receiving NHF may have been unnecessarily escalated to an on-site PICU because of the perception that they were sicker.

#### Points of interest

The NHF group had higher PICU admissions. However, 88% of the NHF group remained on NHF and did not NHF 12.5% SOT 6.9% require therapy escalation. Escalation of care in

NHF 2.3%

SOT 2.2%

### Starting flow rates and weaning strategies

# **Optiflow Junior 2 interface product features**

#### Starting flow rate

- 2 L/kg/min for patients up to 15 kg in weight has been shown to produce a rapid improvement in respiratory distress, and a reduced need for escalation of therapy.
- Weight-banding flow rates for > 15 kg have been protocolized by the PARIS 2<sup>1</sup> and FIRST-ABC<sup>2</sup> research groups.

Weight (kg)	≤ 15	16 - 30	31 - 50	> 50
Starting flow rate	2 L/min/kg	35 L/min	40 L/min	50 L/min

#### Weaning off NHF therapy

#### PARIS (ED)<sup>1</sup>

Once stable, infants were weaned to 21% FiO<sub>2</sub>, with no changes to set flow rate.

#### Stopping therapy

NHF therapy was stopped after 1 hour.

#### FIRST-ABC (PICU)<sup>2</sup>

When  $FiO_2$  was  $\leq 0.40$  patients were changed to receive weaning flow rates based on the patient.

#### Stopping therapy

When  $FiO_2 < 30\%$  and/or mild respiratory distress, NHF was stopped.



# F&P Airvo<sup>™</sup> 3 Optiflow System









wkGA = weeks of gestation; mo = months; yr = years. \* Weight data is based on F&P product validation studies. \*\* Age data is a correlation to weight data based on a combination of Fenton, WHO and CDC growth charts.

# Interface size and flow rates



Cerpa F, Cáceres D, Romero-Dapueto C, Giugliano-Jaramillo C, Pérez R, Budini H, Hidalgo V, Gutiérrez T, Molina J, Keymer J. Suppl 2: M5: Humidification on Ventilated Patients: Heated Humidifications or Heat and Moisture Exchangers? The Open Respiratory Medicine Journal. 2015;9:104.

Collins CL, Barfield C, Horne RS, Davis PG. A comparison of nasal trauma in preterm infants extubated to either heated humidified high-flow nasal cannulae or nasal continuous positive airway pressure. European Journal of Pediatrics. 2014 Feb;173:181–6.

Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. The Journal of Pediatrics. 2013 May 1;162(5):949–54.

de Klerk A. Humidified high-flow nasal cannula: is it the new and improved CPAP? Advances in Neonatal Care. 2008 Apr 1;8(2):98-106.

Franklin D, Babl FE, George S, Oakley E, Borland ML, Neutze J, Acworth J, Craig S, Jones M, Gannon B, Shellshear D. Effect of early high-flow nasal oxygen vs standard oxygen therapy on length of hospital stay in hospitalized children with acute hypoxemic respiratory failure: the PARIS-2 Randomized Clinical Trial. JAMA. 2023 Jan 17;329(3):224–34.

Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, Dalziel SR. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. New England Journal of Medicine. 2018 Mar 22;378(12):1121–31.

Gc VS, Franklin D, Whitty JA, Dalziel SR, Babl FE, Schlapbach LJ, Fraser JF, Craig S, Neutze J, Oakley E, Schibler A. First-line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service. Archives of Disease in Childhood. 2020 Oct 1;105(10):975–80.

Hough JL, Pham TM, Schibler A. Physiologic effect of high-flow nasal cannula in infants with bronchiolitis. Pediatric Critical Care Medicine. 2014 Jun 1;15(5):e214–9.

Kepreotes E et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. The Lancet. 2017; 389, 930-39. McKiernan C, Chua L, Visintainer P, Allen H. High-flow nasal cannulae therapy in infants with bronchiolitis. The Journal of Pediatrics. 2010;156(4), 634-38.

Mayfield S, Bogossian F, O'Malley L, Schibler A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. Journal of Paediatrics and Child Health. 2014 May;50(5):373–8.

Milési C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, Cambonie G. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Med. 2013 Jun;39(6):1088-94.

Milési C, Essouri S, Pouyau R, Liet JM, Afanetti M, Portefaix A, Baleine J, Durand S, Combes C, Douillard A, Cambonie G; Groupe Francophone de Réanimation et d'Urgences Pédiatriques (GFRUP). High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study). Intensive Care Med. 2017 Feb;43(2):209-16.

Ramnarayan P, Richards-Belle A, Drikite L, Saull M, Orzechowska I, Darnell R, Sadique Z, Lester J, Morris KP, Turne LN, Davis PJ. Effect of high-flow nasal cannula therapy vs continuous positive airway pressure therapy on liberation from respiratory support in acutely ill children admitted to pediatric critical care units: a randomized clinical trial. JAMA. 2022 Jul 12;328(2):162–72.

Ramnarayan P, Richards-Belle A, Drikite L, Saull M, Orzechowska I, Darnell R, Sadique Z, Lester J, Morris KP, Tume LN, Davis PJ. Effect of high-flow nasal cannula therapy vs continuous positive airway pressure following extubation on liberation from respiratory support in critically ill children: a randomized clinical trial. JAMA. 2022 Apr 26;327(16):1555–65.

Richards-Belle A, Davis P, Drikite L et al. FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC): a master protocol of two randomised trials to evaluate the non-inferiority of high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care. BMJ Open. 2020;10:e038002. Roberts CT, Owen LS, Manley BJ, Frøisland DH, Donath SM, Dalziel KM, Pritchard MA, Cartwright DW, Collins CL, Malhotra A, Davis PG. Nasal high-flow therapy for primary respiratory support in preterm infants. New England Journal of Medicine. 2016 Sep 22;375(12):1142–51.

Rubin S et al. Effort of breathing in children receiving high-flow nasal cannula. Pediatr Crit Care Med. 2014;15, 1-6.

Saslow JG, Aghai ZH, Nakhla TA, Hart JJ, Lawrysh R, Stahl GE, Pyon KH. Work of breathing using high-flow nasal cannula in preterm infants. Journal of Perinatology. 2006 Aug;26(8):476–80.

Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Medicine. 2011 May;37:847–52.

Sinha IP, McBride AK, Smith R, Fernandes RM. CPAP and high-flow nasal cannula oxygen in bronchiolitis. Chest. 2015 Sep 1;148(3):810–23.

Testa G et al. Comparative evaluation of high-flow nasal cannula and conventional oxygen therapy in paediatric cardiac surgical patients: a randomized controlled trial. Interact Cardiovasc Thorac Surg. 2014;19: 456-61.

Wilkinson D, Andersen C, O'Donnell CP, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. Cochrane Database of Systematic Reviews. 2016 (2).

Willer RJ, Johnson MD, Cipriano FA, Stone BL, Nkoy FL, Chaulk DC, Knochel ML, Kawai CK, Neiswender KL, Coon ER. Implementation of a weight-based high-flow nasal cannula protocol for children with bronchiolitis. Hospital Pediatrics. 2021 Aug 1;11(8):891–5.

Wing R, James C, Maranda LS, Armsby CC. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatric Emergency Care. 2012 Nov 1;28(11):117–23.

Yoder BA, Stoddard RA, Li M, King J, Dirnberger DR, Abbasi S. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. Pediatrics. 2013 May 1;131(5):e1482–90.

F&P, AirSpiral, Airvo, FlexiTube, Optiflow, Waveflex and Wigglepads are trademarks of Fisher & Paykel Healthcare. For patent information, please see www.fphcare.com/ip.

626007 REV D © 2024 Fisher & Paykel Healthcare Limited.



#### www.fphcare.com